open access

Vol 66, No 2 (2015)
Original papers
Published online: 2015-05-01
Submitted: 2015-03-08
Accepted: 2015-03-16
Get Citation

Dosage and costs of lanreotide Autogel 120 mg administered as part of routine acromegaly care in Poland — two years of data from Lanro-Study

Ewa Orlewska, Beata Kos-Kudla, Jerzy Sowinski, Krzysztof Sworczak, Wojciech Zgliczynski, Lanro-Study Group
DOI: 10.5603/EP.2015.0022
·
Endokrynologia Polska 2015;66(2):142-148.

open access

Vol 66, No 2 (2015)
Original papers
Published online: 2015-05-01
Submitted: 2015-03-08
Accepted: 2015-03-16

Abstract

Introduction: To evaluate, over 24 months of prospective follow-up, the dosage and costs of lanreotide AUTOGEL 120 mg (ATG120) administered as part of routine acromegaly care in Poland.
Material and methods: A multicentre, non-interventional, observational prospective study on resource utilisation in Polish acromegalic patients treated with ATG120 at 4-week or extended (> 4 weeks) dosing interval. The study population consisted of adult acromegalic patients treated for at least 3 injections of ATG120. The endpoints were: percentage of patients treated with ATG120 at an extended dosing interval (> 4 weeks), mean time between injections, and the cost of ATG120 during a 24-month prospective observation. Costs were calculated in PLN from the public health-care payer and patient perspective for the year 2014.
Results: 143 patients were enrolled in, and 132 completed (70% women, 81% macroadenoma, 75% previous surgery) the analysis. During two years, changes in the treatment pattern were reported in 41 patients: 17% of them had increased injection interval and 10% switched to octreotide LAR and then returned to ATG120. Sixty-three patients (48%) received ATG120 at an extended dosing interval. ATG120 was predominantly administered in an out-patient setting (84%) by a health care professional (97%).
Conclusions: The results demonstrated that extended dosing interval of ATG120 is used in a substantial proportion of patients in routine clinical practice in Poland. Such findings support the potential for ATG120 in reducing treatment burden in the real-world clinical environment. (Endokrynol Pol 2015; 66 (2): 142–148)

Abstract

Introduction: To evaluate, over 24 months of prospective follow-up, the dosage and costs of lanreotide AUTOGEL 120 mg (ATG120) administered as part of routine acromegaly care in Poland.
Material and methods: A multicentre, non-interventional, observational prospective study on resource utilisation in Polish acromegalic patients treated with ATG120 at 4-week or extended (> 4 weeks) dosing interval. The study population consisted of adult acromegalic patients treated for at least 3 injections of ATG120. The endpoints were: percentage of patients treated with ATG120 at an extended dosing interval (> 4 weeks), mean time between injections, and the cost of ATG120 during a 24-month prospective observation. Costs were calculated in PLN from the public health-care payer and patient perspective for the year 2014.
Results: 143 patients were enrolled in, and 132 completed (70% women, 81% macroadenoma, 75% previous surgery) the analysis. During two years, changes in the treatment pattern were reported in 41 patients: 17% of them had increased injection interval and 10% switched to octreotide LAR and then returned to ATG120. Sixty-three patients (48%) received ATG120 at an extended dosing interval. ATG120 was predominantly administered in an out-patient setting (84%) by a health care professional (97%).
Conclusions: The results demonstrated that extended dosing interval of ATG120 is used in a substantial proportion of patients in routine clinical practice in Poland. Such findings support the potential for ATG120 in reducing treatment burden in the real-world clinical environment. (Endokrynol Pol 2015; 66 (2): 142–148)

Get Citation

Keywords

acromegaly; lanreotide Autogel; clinical study; cost of treatment

About this article
Title

Dosage and costs of lanreotide Autogel 120 mg administered as part of routine acromegaly care in Poland — two years of data from Lanro-Study

Journal

Endokrynologia Polska

Issue

Vol 66, No 2 (2015)

Pages

142-148

Published online

2015-05-01

DOI

10.5603/EP.2015.0022

Bibliographic record

Endokrynologia Polska 2015;66(2):142-148.

Keywords

acromegaly
lanreotide Autogel
clinical study
cost of treatment

Authors

Ewa Orlewska
Beata Kos-Kudla
Jerzy Sowinski
Krzysztof Sworczak
Wojciech Zgliczynski
Lanro-Study Group

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl